Skye Bioscience Provides 2025 Look Ahead and Year in Review
Skye Bioscience, Inc. (SKYE)
Company Research
Source: GlobeNewswire
SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company developing new therapeutic pathways for metabolic health, enters 2025 positioned to announce Phase 2 data for nimacimab, a non-incretin mechanism and first-in-class, peripherally-restricted CB1 inhibitor antibody with the potential to enhance important facets of obesity treatment while achieving significant weight loss. Skye’s goal in 2025 is to achieve clinical milestones and new scientific insights related to the unique effects and metabolic mechanisms of peripheral CB1 inhibition. “The understanding of mechanisms and opportunities to best treat obesity and overweight is still early in its evolution. There is
Read more
Impact Snapshot
Event Time:
SKYE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SKYE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SKYE alerts
High impacting Skye Bioscience, Inc. news events
Weekly update
A roundup of the hottest topics
SKYE
News
- Skye Bioscience, Inc. (NASDAQ: SKYE) had its price target lowered by analysts at Craig Hallum from $18.00 to $14.00. They now have a "buy" rating on the stock.MarketBeat
- Skye Bioscience, Inc. (NASDAQ: SKYE) had its "outperform" rating re-affirmed by analysts at William Blair.MarketBeat
- Skye Bioscience, Inc. (SKYE) Q4 2024 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateGlobeNewswire
SKYE
Earnings
- 3/20/25 - Beat
SKYE
Sec Filings
- 3/20/25 - Form S-8
- 3/20/25 - Form 8-K
- 3/20/25 - Form 10-K
- SKYE's page on the SEC website